Abstract CT079: Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial
Year: 2023
Type: conference-abstract
Source: Cancer Research
Authors: Qinglei Gao, Jing Wang, Qin Xu, Ying Tang, Jieqing Zhang, Baoping Chang, Bairong Xia, Wei Duan, Danbo Wang, Lijing Zhu, Ruifang An, Guonan Zhang, Yaling Tang, Jianli Huang, Xiang Zhang, Hui Qiu, Wenting Ji, Li Li, Jianqing Zhu, Ding Ma
Institutions: Tongji Hospital, Huazhong University of Science and Technology, Hunan Cancer Hospital, Fujian Medical University, Fujian Provincial Cancer Hospital, Chongqing University, First Affiliated Hospital of Xiamen University, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, First Affiliated Hospital of Henan University of Science and Technology, University of Science and Technology of China, Capital Medical University, Beijing Obstetrics and Gynecology Hospital, Liaoning Cancer Hospital & Institute, Nanjing Drum Tower Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Sichuan Cancer Hospital, Zhangzhou Municipal Hospital of Fujian Province, Zhejiang Cancer Hospital, Zhongnan Hospital of Wuhan University, Innovent Biologics (China)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4365513065